TargetSp15-hypoxanthine+phosphoribosyltransferas+(Plasmodium+falciparum+3D7)

Target (protein/gene name): hypoxanthine phosphoribosyltransferase Etiologic Risk Group (see link below): P. falciparum is a bacterium that causes malaria. Malaria causes flu- like symptoms with high fever, body aches, and chills. This particular stand of the bacterium causes malaria that progress into a more extreme form of malaria that causes fatal acute infections. This strain of the diease is mainly seen in Africa. Current treatments include: chloroquine, atovaquone-proguanil (Malarone®), artemether-lumefantrine (Coartem®),mefloquine (Lariam®), but all of these treatments are expensive. Source: http://www.cdc.gov/malaria/diagnosis_treatment/treatment.html http://malaria.wellcome.ac.uk/doc_WTD023865.html Link to TDR Targets page (if present): http://www.tdrtargets.org/targets/view?gene_id=1197 Link to Gene Database page (NCBI, EuPath databases -e.g. TryTryp, PlasmoDB, etc - or PATRIC, etc.): http://www.ncbi.nlm.nih.gov/protein/AAN35319.1 Essentiality of this protein: This protein is essential in the production of purine and pyrimidine bases. Source: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3319363/ Is it a monomer or multimer as biological unit? (make prediction at http://www.ebi.ac.uk/msd-srv/prot_int/pistart.html): 4 amino acid chains and 16 ligands in ASU Complex of proteins?: Tetramer Druggable Target (list number or cite evidence from a paper/database showing druggable in another organism): http://www.ncbi.nlm.nih.gov/pubmed/17149876 Link to BRENDA EC# page: http://www.brenda-enzymes.org/enzyme.php?ecno=2.4.2.8&Suchword=&organism%5B%5D=Plasmodium+falciparum&show_tm=0 -- Show screenshot of BRENDA enzyme mechanism schematic Enzyme Assay information (spectrophotometric, coupled assay ?, reagents):
 * NCBI Gene # or RefSeq#: GI:23494985
 * Protein ID (NP or XP #) or Wolbachia#: AAN35319.1
 * Organism (including strain): Plasmodium falciparum 3D7
 * /Disease Information (sort of like the Intro to your Mini Research Write up):
 * EC#: 2.4.2.8

-- link to Sigma (or other company) page for assay (see Sigma links below)

http://www.sigmaaldrich.com/content/dam/sigma-aldrich/docs/Sigma/Enzyme_Assay/hypoxanthineguanine.pdf

-- links to assay reagents (substrates) pages.

--- List cost and quantity of substrate reagents, supplier, and catalog # Structure (PDB or Homology model)

-- PDB # or closest PDB entry if using homology model: 1CJB Current Inhibitors: Expression Information (has it been expressed in bacterial cells): E.Coli
 * C 11 H 15 N 4 O 7 P || (1S)-1(9-DEAZAHYPOXANTHIN-9YL)1,4-DIDEOXY- 1,4-IMINO-D-RIBITOL-5-PHOSPHATE ||

Purification Method:

Image of protein (PyMol with features delineated and shown separately):
 * Amino Acid Sequence (paste as text only - not as screenshot or as 'code'):

MPIPNNPGAGENAFDPVFVKDDDGYDLDSFMIPAHYKKYLTKVLVPNGVIKNRIEKLAYDIKKVYNNEEF HILCLLKGSRGFFTALLKHLSRIHNYSAVETSKPLFGEHYVRVKSYCNDQSTGTLEIVSEDLSCLKGKHV LIVEDIIDTGKTLVKFCEYLKKFEIKTVAIACLFIKRTPLWNGFKADFVGFSIPDHFVVGYSLDYNEIFRDLDHCCLVNDEGKKKYKATSL Molecular Weight of your protein in kDaltons using the Expasy ProtParam website: 26.362 kDa Molar Extinction coefficient of your protein at 280 nm wavelength: 23755 TMpred graph Image (http://www.ch.embnet.org/software/TMPRED_form.html). Input your amino acid sequence to it.: Do Not Need this info for Spring (but still copy these lines to your Target page for now) Primer design results for pNIC-Bsa4 cloning (list seqeunces of all of your ~40 nt long primers): (link to DNA Works output text file - that should be saved in your Google Docs folder after you did the primer design protocol) -- Ask a mentor, Dr. B, or a fellow researcher -how to link a GDocs file if you are not sure how to. Primer design results for 'tail' primers (this is just 2 sequences):
 * length of your protein in Amino Acids: 231 amino Acids
 * CDS Gene Sequence (paste as text only):
 * GC% Content for gene:
 * CDS Gene Sequence (codon optimized) - copy from output of Primer Design Protocol (paste as text only):
 * GC% Content for gene (codon optimized):